Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Calogero Vetro

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Frontiers in Pharmacology|May 12, 2017
Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk MyelodysplasiaAlessandra Romano, Cesarina Giallongo, Piera La Cava, et al.
Journal of Clinical Medicine|July 29, 2025
Real-World Outcomes in <i>FLT3</i>-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric CohortVeronica Vecchio, Andrea Duminuco, Salvatore Leotta, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic LandscapeAndrea Duminuco, Patrick Harrington, Vittorio Del Fabro, et al.
Frontiers in Immunology|October 9, 2023
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experienceAndrea Duminuco, Uros Markovic, Nunziatina Laura Parrinello, et al.
Journal of Clinical Medicine|March 25, 2022
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic SyndromesCalogero Vetro, Valeria Di Giacomo, Donato Mannina, et al.
Journal of Clinical Medicine|July 29, 2025
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with VenetoclaxFanny Erika Palumbo, Andrea Duminuco, Laura Longo, et al.
Genes|February 27, 2026
Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage ModelAndrea Duminuco, Silvia Rita Vitale, Antonella Nardo, et al.
Leukemia & Lymphoma|May 7, 2015
Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center studyMariasanta Napolitano, Luca Valore, Alessandra Malato, et al.
Journal of Clinical Medicine|August 14, 2025
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational StudyErmelinda Longo, Fanny Erika Palumbo, Andrea Duminuco, et al.
Blood|March 22, 2015
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cellsMaria Paola Martelli, Ilaria Gionfriddo, Federica Mezzasoma, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Frontiers in Pharmacology|May 12, 2017
Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk MyelodysplasiaAlessandra Romano, Cesarina Giallongo, Piera La Cava, et al.
Journal of Clinical Medicine|July 29, 2025
Real-World Outcomes in <i>FLT3</i>-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric CohortVeronica Vecchio, Andrea Duminuco, Salvatore Leotta, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic LandscapeAndrea Duminuco, Patrick Harrington, Vittorio Del Fabro, et al.
Frontiers in Immunology|October 9, 2023
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experienceAndrea Duminuco, Uros Markovic, Nunziatina Laura Parrinello, et al.
Journal of Clinical Medicine|March 25, 2022
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic SyndromesCalogero Vetro, Valeria Di Giacomo, Donato Mannina, et al.
Journal of Clinical Medicine|July 29, 2025
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with VenetoclaxFanny Erika Palumbo, Andrea Duminuco, Laura Longo, et al.
Genes|February 27, 2026
Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage ModelAndrea Duminuco, Silvia Rita Vitale, Antonella Nardo, et al.
Leukemia & Lymphoma|May 7, 2015
Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center studyMariasanta Napolitano, Luca Valore, Alessandra Malato, et al.
Journal of Clinical Medicine|August 14, 2025
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational StudyErmelinda Longo, Fanny Erika Palumbo, Andrea Duminuco, et al.
Blood|March 22, 2015
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cellsMaria Paola Martelli, Ilaria Gionfriddo, Federica Mezzasoma, et al.
Pageof 7